Overview

A Study of EDP-323 in Healthy Subjects

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Enanta Pharmaceuticals, Inc